Form D · Manufacturing
Enduraphin, Inc.
Binghamton, NY · CIK 0001741981
Offering snapshot reported May 25, 2018 · SEC filing
- Reported sold
- $100K Indefinite offering
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- May 24, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 25, 2018 | Initial | $100,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-313311
S.A.F.E. (simple agreement for future equity)
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed May 25, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael S Dalberth | Director, Executive |
| Daniel M Drake | Director, Executive |
Issuer details
Industry: Manufacturing (See others in industry)
Address:
120 Hawley Street
Binghamton, NY, 13901
Binghamton, NY, 13901